# Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

> **NCT07372079** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer
- Neoadjuvant Therapy
- Immune Checkpoint Inhibitors
- QL1706

## Interventions

- **DRUG:** QL1706 combined with Chemotherapy

## Key facts

- **NCT ID:** NCT07372079
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-05
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07372079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07372079, "Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07372079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*